# MDxHealth (MDXH) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/MDXH
## Company Profile
- Ticker: MDXH
- Exchange: NASDAQ
- Sector: MedTech
- Location: Belgium and listed in the U
- Tags: Diagnostics, Oncology
## Stock Data
- Close: 0.4696 USD
- Market cap: 32934930.224 USD
- Last updated: 2026-08-12
## Business Overview
### Precision Urologic Diagnostics
MDxHealth provides molecular tests that support diagnosis, risk assessment, and treatment decisions in prostate cancer and other urologic diseases.
### Prostate Cancer Menu
The company’s portfolio spans pre-biopsy risk assessment, tissue-based prognostic testing, and post-treatment monitoring, using genomic, epigenomic, and exosomal technologies.
### ExoDx Integration
The acquired ExoDx urine-based prostate test broadens the diagnostic menu and is being integrated into MDxHealth’s laboratory, sales, and reimbursement infrastructure.
### Portfolio Refocus
MDxHealth is exiting the Resolve UTI business to concentrate investment on prostate cancer and related urologic oncology opportunities.
## Why The Stock Is Moving

The latest monitored company update is “Mdxhealth Reports Second Quarter 2026 Financial Results.” The corresponding closing-price reaction is not yet available.

## Recent News
- 2026-08-13 20:00 EST — [Mdxhealth Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/MDXH/mdxhealth-reports-second-quarter-2026-financial-results-5edfb69f) — Source: MDxHealth
- 2026-07-30 20:00 EST — [Mdxhealth to Release Second Quarter 2026 Financial Results on August 13](https://biopharmsignal.com/news/MDXH/mdxhealth-to-release-second-quarter-2026-financial-results-on-august-13-3e04359c) — Source: MDxHealth
- 2026-07-24 20:59 EST — [Mdxhealth Announces Receipt of Nasdaq Notification Regarding  Minimum Market Value of Listed Securities Deficiency](https://biopharmsignal.com/news/MDXH/mdxhealth-announces-receipt-of-nasdaq-notification-regarding-minimum-market-valu-cf439d90) — Source: MDxHealth
- 2026-07-02 20:00 EST — [Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency](https://biopharmsignal.com/news/MDXH/mdxhealth-announces-receipt-of-nasdaq-notification-regarding-minimum-bid-price-d-bdf178d6) — Source: MDxHealth
- 2026-06-29 12:00 EST — [Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial](https://biopharmsignal.com/news/MDXH/mdxhealth-announces-peer-reviewed-publication-of-oxford-gps-prompt-study-in-euro-d931d4ac) — Source: MDxHealth